Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Catapres-TTS

The nurse instructs the patient using the transder-mal system (Catapres TTS). ... [Pg.406]

Carcizem 29 Cardura 30 Carisoprodd 21, 82 Cartedol 21 Cartrol 21 Catvedilol 21 Casanthranol 79 Catapres 25 Catapres-TTS 25 Cedor 21 Cedax 22... [Pg.78]

Transdermal system 2.5 mg (release rate 0.1 mg/24 h) Rx) Catapres-TTS-1 (Boehringer-Ingelheim)... [Pg.552]

Brand Name(s) Catapres, Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Clonidine... [Pg.288]

Clonidine is also available as a transdermal patch (Catapres-TTS [transdermal therapeutic system]) that has the advantages of avoiding the need for repeated doses during the day and of reportedly lower rates of dry mouth and drowsiness (Burris, 1993). Steady-state plasma levels are reached within 2-3 days after applying the patch and clonidine concentrations reportedly diminish gradually over 2-3 days following patch removal, without rebound hypertension in adult hyper-... [Pg.531]

Transdermal (Catapres-TTS) patches that release 0.1, 0.2, 0.3 mg/24 h Guanabenz (generic, Wytensin)... [Pg.245]

Transdermal Transderm-Scop transdermal patch system Catapres-TTS transdermal system... [Pg.58]

Figure 8.7 Plasma concentration of clonidine versus time profile during and subsequent to the 7-day application of a 5 cm2 Catapres-TTS patch (Modified from Rnepp, V.M. Hadgraft, J. and Guy, R.H. (1987) CRC Critical Reviews in Therapeutic Drug Carrier Systems. 4, 13-37)... Figure 8.7 Plasma concentration of clonidine versus time profile during and subsequent to the 7-day application of a 5 cm2 Catapres-TTS patch (Modified from Rnepp, V.M. Hadgraft, J. and Guy, R.H. (1987) CRC Critical Reviews in Therapeutic Drug Carrier Systems. 4, 13-37)...
Clonidine is a potent antihypertensive agent which is well absorbed from the GI tract (95%). The dmg has a relatively long half-life (6-20 h) and a modest clearance (13 L h ). The rationale for the development of transdermal clonidine was to reduce side-effects and to improve patient compliance. Catapres-TTS, a reservoir-type patch, reached the market in 1985 in a form designed to remain in place and to deliver dmg for 7 days. Dose titration was possible via the use of systems of different active areas (3.5, 7.0, and 10.5 cm2). The control of dmg delivery over 7 days is impressive, and avoids the peaks and valleys of conventional (twice-a-day) oral administration (Figure 8.7). However, this system has not achieved as wide a success as first seemed likely because of skin sensitization. Clonidine itself, when administered transdermally on a chronic, repetitive basis, induces in a significant fraction of patients a classic immunologic skin reaction, and this has severely attenuated its use. [Pg.205]

Catapres TTS is the first and only transdermal patch approved by the FDA for the treatment of hypertension. Catapres TTS contains the active ingredient clondidine and was approved in 1985 [27], Catapres TTS is a seven-day patch and is a membrane-moderated transdermal patch. The patch comes in three sizes, 0.1, 0.2, and 0.3 mg/day. In addition there is also a burst dose of clonidine in the adhesive layer. The presence of the burst doses provides an immediate-release dose of clonidine which promotes rapid systemic levels of the drug. [Pg.801]

Pharmacia and Upjohn, Kalamazoo, MI) and Cri-none Gel (Wyeth-Ayerst). Mineral oil is frequently present in transdermal products such as Catapres-TTS (Boehringer Ingelheim) and Estraderm (Novartis Pharmaceuticals Corp). In addition, numerous ocular or topical ointments, such as TobraDex (Alcon Labs, Fort Worth, TX) and Nitro-Bid (Hoechst Marion Roussel, Kansas City, MO), use white petrolatum and mineral oil as a base. Short-chain triglycerides such as triacetin can be found in products such as Prepidil Gel (Pharmacia-Upjohn, Kalamazoo MI), a cervically administered prostaglandin. [Pg.984]

Fig. 14 Cross-section view of various structural components in the Transderm-Scop and Catapres-TTS systems. Fig. 14 Cross-section view of various structural components in the Transderm-Scop and Catapres-TTS systems.
The popular Transdermal Scop patches are widely used by travelers who experience motion sickness, and contain 1.5 mg of scopolamine solubilized to approximately 100 mg/ml in mineral oil, and deliver 1.0 mg over three days. Catapres -TTS patches contain 2.5-7.5 mg of clonidine solubilized in mineral oil, and deliver 0.1-0.3 mg/day for seven days. Vivelle-DOT patches contain 0.39-1.6 mg of estradiol solubilized in... [Pg.3362]

Clonidine (CL) Male and female (20-39) Arm, thigh, chest Catapres-TTS patch (Boehringer Ingelheim, Germany) CL concentration in blood and urine CL concentration in plasma and urine samples chest > upper arm > thigh. Correlation found between CL release from patch and AUC. V... [Pg.3817]

Clonidine (CL) Male (18-45) Chest, arm Catapres-TTS patch CL concentration in plasma Similar pharmacokinetic profile between sites ... [Pg.3817]

Hopkins, K. Ararons, L. Rowland, M. Absorption and excretion of clonidine following application of catapres-TTS to different skin sites. In Low Dose Oral and Transdermal Therapy of Hypertension, Weber, M.A., Drayer, J.I.M., Kolloch, R., Eds. Steinkopff Verlag Darmstadt, Germany, 1985 134-137. [Pg.3825]

See other pages where Catapres-TTS is mentioned: [Pg.174]    [Pg.239]    [Pg.141]    [Pg.215]    [Pg.403]    [Pg.130]    [Pg.15]    [Pg.552]    [Pg.552]    [Pg.40]    [Pg.116]    [Pg.288]    [Pg.39]    [Pg.116]    [Pg.174]    [Pg.126]    [Pg.282]    [Pg.454]    [Pg.794]    [Pg.801]    [Pg.117]    [Pg.81]    [Pg.282]    [Pg.455]    [Pg.1087]    [Pg.3363]   
See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.116 ]



SEARCH



Catapre

Catapres-TTS patches

© 2024 chempedia.info